Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
86964 trials found · Page 93 of 4349
-
Major trial aims to extend lives in advanced lung cancer
Disease control OngoingThe purpose of this study is to assess the efficacy and safety of platinum-based chemotherapy with or without INCMGA00012 in participants with metastatic squamous and nonsquamous non-small cell lung cancer (NSCLC).
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Apr 06, 2026 14:05 UTC
-
New pill shows promise against hard-to-treat lung cancer mutation
Disease control CompletedThis is a randomized, positive-controlled, open-label, international multicenter, Phase 3 clinical study to compare the efficacy and safety of pyrotinib versus docetaxel in patients with advanced non-squamous NSCLC harboring a HER2 exon 20 mutation who failed platinum based chemo…
Phase: PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Apr 26, 2026 20:01 UTC
-
Good bugs vs. bad bugs: can infected mosquitoes stop dengue?
Prevention CompletedThis is a cluster randomized controlled trial (CRCT) to evaluate the efficacy of Wolbachia-infected A. aegypti mosquito releases in reducing the burden of ARBV infection in Brazil over four years. The intervention will be the release of Wolbachia-infected A. aegypti mosquitoes. S…
Phase: NA • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Prevention
Last updated Apr 26, 2026 19:35 UTC
-
New vaccine aims to block more Cancer-Causing HPV strains
Prevention OngoingThis phase III clinical study was designed to evaluate the efficacy,immunogenicity and safety of Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type)(E.Coli) manufactured by Xiamen Innovax Biotech CO., LTD., in healthy women aged 18-45 years old.
Phase: PHASE3 • Sponsor: Xiamen University • Aim: Prevention
Last updated Apr 20, 2026 16:19 UTC
-
Double-Drug attack on blood cancer shows promise
Disease control Recruiting nowThis phase I/II clinical trial evaluates the safety and efficacy of the combined administration of midostaurin and gemtuzumab ozogamicin in the frame of first-line standard chemotherapy in newly diagnosed acute myeloid leukemia (AML) patients displaying a cytogenetic aberration o…
Phase: PHASE1, PHASE2 • Sponsor: Technische Universität Dresden • Aim: Disease control
Last updated Apr 20, 2026 16:17 UTC
-
New hope for lymphoma patients Who've run out of options
Disease control Recruiting nowThe purpose of this Phase 2/3 study is to evaluate efficacy and safety of the combination of selinexor and R-GDP (SR-GDP) in patients with RR DLBCL who are not intended to receive hematopoetic stem cell transplantation (HSCT) or chimeric antigen receptor T cell (CAR-T) therapy. T…
Phase: PHASE2, PHASE3 • Sponsor: Karyopharm Therapeutics Inc • Aim: Disease control
Last updated Apr 07, 2026 14:37 UTC
-
New hope to stop breast Cancer's return in High-Risk patients
Disease control OngoingPatients with breast cancer, who have completed first line therapy (e.g., radiotherapy, chemotherapy, surgery), and who have to be identified with having a high risk of recurrence of cancer, will be eligible for the study. This patient group is currently offered a standard of car…
Phase: PHASE3 • Sponsor: West German Study Group • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
20,000 seniors test statin for dementia prevention
Prevention Recruiting nowPREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia wi…
Phase: PHASE4 • Sponsor: Duke University • Aim: Prevention
Last updated Apr 26, 2026 20:02 UTC
-
Umbilical cord patch may shield babies from spina bifida damage before birth
Disease control OngoingTo fetoscopically use cryopreserved human umbilical cord allografts, named NEOX Cord 1K®, as a spinal cord cover of spina bifida defects. This procedure will be performed to create a watertight seal covering over the spinal cord in order to decrease the incidence rates of postnat…
Phase: NA • Sponsor: The University of Texas Health Science Center, Houston • Aim: Disease control
Last updated Apr 26, 2026 20:02 UTC
-
Freeze and fight: new combo therapy trial aims to extend lives in advanced lung cancer
Disease control Recruiting nowThis study aims to compare the one-year survival benefit of the association of cryoablation-pembrolizumab-pemetrexed-carboplatin versus pembrolizumab-pemetrexed-carboplatin in metastatic lung adenocarcinoma patients. This is a multicenter, prospective, open-labeled, 2-arm compar…
Phase: PHASE3 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Apr 20, 2026 16:17 UTC
-
New weapon in ovarian cancer fight? major trial tests Immune-Boosting drug
Disease control OngoingStudy to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian cancer who have u…
Phase: PHASE3 • Sponsor: CanariaBio Inc. • Aim: Disease control
Last updated Apr 20, 2026 16:15 UTC
-
New drug duo shows promise against tough liver cancer
Disease control CompletedThis is a Phase IIIb, one arm, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab + bevacizumab in patients with unresectable HCC who have received no prior systemic treatment.
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Apr 13, 2026 20:16 UTC
-
Gene therapy shot could replace monthly eye injections for wet AMD
Disease control OngoingThis interventional study is being conducted with an investigational gene therapy treatment called ABBV-RGX-314 (also known as RGX-314) and is being developed as a potential one-time gene therapy treatment for neovascular (wet) age-related macular degeneration (wet AMD or nAMD). …
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Apr 24, 2026 16:07 UTC
-
Promising antibody targets deadly protein clumps in rare disease
Disease control OngoingAL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down. These free light chains bind together to form amyloid fibrils that build up in the extracellular space of organs, affecting the kidne…
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 26, 2026 19:35 UTC
-
New drug combo challenges standard treatment for advanced lung cancer
Disease control CompletedThe purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab in participants with locally advanced, unresectable Stage III non-small cell lung cancer (NSCLC) who have received at least two cycles of conc…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Apr 22, 2026 15:58 UTC
-
Can a short, early blitz of powerful drugs stop arthritis for good?
Disease control OngoingThe SPARTACUS study will explore the therapeutic efficacy of 2 different treatment strategies for patients suffering from peripheral Spondyloarthritis (pSpA), classified according to the "Assessment in SpondyloArthritis international Society" (ASAS) classification criteria; it wi…
Phase: PHASE3 • Sponsor: University Hospital, Ghent • Aim: Disease control
Last updated Apr 08, 2026 12:11 UTC
-
Gentler transplant offers hope for rare disease patients
Disease control Recruiting nowThis is a data collection study that will examine the general diagnostic and treatment data associated with the reduced-intensity chemotherapy-based regimen paired with simple alemtuzumab dosing strata designed to prevented graft failure and to aid in immune reconstitution follow…
Sponsor: Paul Szabolcs • Aim: Disease control
Last updated Apr 13, 2026 20:22 UTC
-
New combo therapy battles advanced kidney cancer in major trial
Disease control CompletedThis is a randomized, open-label, controlled, multicenter, phase III trial to compare the efficacy and safety of Toripalimab in combination with axitinib to sunitinib monotherapy as a first-line therapy for advanced RCC. Eligible patients will be randomized 1:1 to receive the com…
Phase: PHASE3 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Apr 06, 2026 14:05 UTC
-
New device could save legs from amputation in severe artery disease
Disease control OngoingThe objective of this prospective, single-blinded, randomized controlled clinical investigation is to evaluate the safety and efficacy of the everolimus eluting Esprit BTK System for the planned treatment of narrowed infrapopliteal lesions. Approximately 225 subjects will be rand…
Phase: NA • Sponsor: Abbott Medical Devices • Aim: Disease control
Last updated Apr 24, 2026 16:17 UTC
-
Breakthrough implant lets amputees 'Feel' with their prosthetic hand
Disease control Recruiting nowThe purpose of this research is to gather information on the safety and effectiveness of an implanted wireless sensory enabled highly intuitive controlled prosthetic device.
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Apr 13, 2026 20:23 UTC